|
|
Home > Healthcare > Biotechnology > Genetics & Genomics
Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and development
|
| Published Date:
April 2009
Published By:
Datamonitor
Page Count:
69
Order Code:
R313-50617
|
|
|
|
Introduction
Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.
Scope- Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
- Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
- Unmet needs and research priorities in the field of HSCT
- Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights
The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.
The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.
The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.
Reasons to Purchase- Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
- Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
- Identify unmet needs and research priorities in the field of HSCT
Please note: this is delivered as a Zip file.
|
Similar Products
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• The Human Genome Sequencing Center at Baylor College of Medicine Relies on Quantum's StorNext Software for Data Management
Published Oct 2009 by IDC
• Transfection Life Science Dashboard™ Series 2
Published Oct 2009 by Percepta Associates, Inc.
• Genealogy Products and Services
Published Oct 2009 by Global Industry Analysts
• Preventive Healthcare Technologies, Products and Markets
Published Oct 2009 by BCC Research
• Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook
Published Oct 2009 by Business Insights
• Genetic Diseases and Dysmorphic Syndromes Gaucher's Disease Therapy Area Pipeline Report
Published Sep 2009 by Life Science Analytics (LSA)
• Genetic Diseases and Dysmorphic Syndromes Wilson Disease Therapy Area Pipeline Report
Published Sep 2009 by Life Science Analytics (LSA)
• Genetic Diseases and Dysmorphic Syndromes Turner's Syndrome Therapy Area Pipeline Report
Published Sep 2009 by Life Science Analytics (LSA)
• Biomarkers- Advanced Technologies and Global Market (2009-2014)
Published Sep 2009 by MarketsandMarkets
|
|
|
|
0 items
